Keyphrases
Malignancy
100%
Acute Megakaryoblastic Leukemia
100%
Megakaryocytic
100%
Novel Therapies
100%
Primary Myelofibrosis
60%
Megakaryocytes
40%
Alisertib
40%
Blood Cancer
40%
Myeloproliferative Neoplasms
40%
Polyploid
40%
Phase 1 Clinical Trial
20%
Small Molecule Screen
20%
PAK1
20%
Sampling Model
20%
RNAi Screen
20%
Drug Development
20%
Polyploidy
20%
In Vitro Activity
20%
Associate Professor
20%
Research Assistants
20%
Children with Down Syndrome
20%
Small Molecules
20%
High-throughput
20%
Cancer Research
20%
Hematological Malignancies
20%
MLN8237
20%
Novel Therapeutics
20%
DYRK1A Inhibitor
20%
Cohesin
20%
Cell Division
20%
Patient Samples
20%
Antitumor Activity
20%
Normal Development
20%
Mouse Model
20%
New Therapies
20%
Aurora Kinase A (AURKA)
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Megakaryocytic Leukemia
100%
Myeloid metaplasia
60%
Alisertib
60%
Myeloproliferative Neoplasm
40%
Malignant Neoplasm
20%
Mouse Model
20%
Preclinical Study
20%
Drug Development
20%
Clinical Trial
20%
Hematologic Malignancy
20%
Down Syndrome
20%
Neoplasm
20%
Cohesin
20%
Aurora A Kinase
20%